Keytruda Meets Its First Clone as Its mRNA Partner Misses

Keytruda, the most successful cancer drug ever, gets its first official biosimilar challenger in the same week that an mRNA cancer vaccine built to pair with it misses its primary endpoint. Is the future of oncology arriving, just not the way anyone drew it up?
In this Monday Morning Oncology Brief (Oct 13–19, 2026), we unpack the three stories that moved the needle:
🔹 BioNTech’s BNT113 misses on progression. The Phase 2/3 AHEAD-MERIT trial failed its PFS endpoint in HPV16+ head and neck cancer, and BioNTech disclosed no numbers. Overall survival is still being tested, so the trial isn’t over. If an mRNA vaccine struggles against an obvious viral target, what does that mean for the field? And how does it compare with Merck and Moderna’s INTerpath-001, which presents at ESMO on Oct 25?
🔹 No chemo, no transplant in Ph+ ALL. NEJM data show ponatinib plus blinatumomab beating imatinib plus chemotherapy as frontline therapy. Nearly nine in ten patients were alive without a disease event at two years, versus about two-thirds on chemo. One expert calls it practice-changing, but is two years of follow-up enough to skip a transplant?
🔹 The first Keytruda biosimilar BLA. The FDA accepted Formycon/Zydus’s FYB206, with a decision expected around Q3 2027. That makes the biosimilar calendar real for a ~$30B franchise, compresses pricing for every Keytruda combination, and raises the stakes for Merck’s subcutaneous defence.
⚡ Lightning round:
• Anktiva’s early label expansion in papillary bladder cancer.
• Gilead and Vir’s $135M upfront deal for masked T-cell engagers.
• Europe follows the US on Revolution Medicines’ daraxonrasib in pancreatic cancer.
• Talvey moves into 2L myeloma in the EU.
• SystImmune’s silent Phase 3 registration for its HER2 ADC in bladder cancer.

From blunt force to precision, oncology is optimizing everything at once. What happens to trial design when the standard of care is this refined?
No episode last week; we were on vacation. Next week: our post-ESMO 2026 episode from Madrid.

#Oncology #mRNA #Leukemia #Biosimilars #Keytruda #BioNTech #ESMO2026 #Pharma #Biotech
Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.

Chapters:
00:00 Keytruda's first clone vs. BioNTech's mRNA stumble
00:33 Welcome to The Oncology Deep Dive
00:55 BioNTech's BNT113 misses its primary endpoint
01:13 How an mRNA cancer vaccine works: the "wanted poster"
01:53 No numbers disclosed: what BioNTech isn't saying
02:26 Why HPV16 was BioNTech's most tractable bet
03:02 The debate: is waiting for overall survival a pivot?
04:19 What to watch: Merck & Moderna's INTerpath-001 at ESMO
04:53 Ph+ leukemia: chemo-free ponatinib + blinatumomab
05:28 Precision strike + matchmaker: how the combo works
05:49 Nine in ten vs. two-thirds: the survival gap
06:21 Practice-changing: no transplant needed?
06:38 The debate: is two years of follow-up enough?
07:11 Keytruda's first biosimilar application
07:36 What a biosimilar is: cloning a vintage wine
08:05 2027: the biosimilar calendar becomes real
08:19 Pricing pressure and Merck's subcutaneous defence
08:46 Lightning round
08:53 Anktiva expands in bladder cancer
09:10 Gilead × Vir: masked T-cell engagers
09:26 Europe follows the US on daraxonrasib
09:45 Talvey moves into earlier myeloma
10:00 SystImmune's silent Phase 3 for T-bren
10:12 From blunt force to precision
10:47 See you in Madrid